No no Gary, I didn't mean to bad mouth Keytruda. I meant as a monotherapy CIs fail in treating GBM but in a recurrent setup, as the the UCLA combo dose down Keytruda percentage, if the combo helps the patient better than DcVaxL as an adjuvent, Merck will do the same approach in all solid cancers if MRK buys us out. The UCLA combo trial is a 3 arm trial I think trying to cure rGBM. Thanks for everything you do Gary!
Market Data 
Markets 
AI
